Clinical resistance to topoisomerase-targeted drugs

Anne Marie C Dingemans, Herbert M. Pinedo, Giuseppe Giaccone

Research output: Contribution to journalArticle

Abstract

This review describes topoisomerase (topo)-mediated drug resistance and topo expression in human tissues and cancers. In some in vitro studies a relation has been observed between topo I, IIα or IIβ expression and sensitivity to topo inhibitors. Drug resistance to topo inhibitors may, however, be multifactorial. Several topo inhibitors are substrates for drug membrane transporters. As most topo inhibitors are cell cycle specific, disturbances in cell cycle regulation can also confer resistance, and downstream events following DNA damage induced by topo inhibitors may be involved in regulating cell death or survival. Several studies in patient specimens have shown a relation between topo IIα expression and the proliferative state of the tumor, higher topo IIα levels being seen in more highly proliferating tumor types. In contrast, topo IIβ appears to be expressed in both proliferating and quiescent cells. Furthermore, higher topo I levels were observed in some tumors when compared to their normal counterparts. In some studies a reduced topo IIα level was seen in samples taken after chemotherapy treatment, as compared with specimens prior to treatment. No unequivocal relation was observed, however, between expression or activity of the topo genes and response to chemotherapy; nonetheless only a few studies have properly addressed this question. This review summarizes the results of the clinical studies performed so far, and analyzes the critical issues in performing studies on patient material.

Original languageEnglish (US)
Pages (from-to)275-288
Number of pages14
JournalBBA - Gene Structure and Expression
Volume1400
Issue number1-3
DOIs
StatePublished - Oct 1 1998
Externally publishedYes

Fingerprint

Topoisomerase Inhibitors
Type II DNA Topoisomerase
Tumors
Type I DNA Topoisomerase
Chemotherapy
Pharmaceutical Preparations
Drug Resistance
Neoplasms
Cell Cycle
Cells
Drug Therapy
Membrane Transport Proteins
Cell death
DNA Damage
Cell Survival
Cell Death
Genes
Tissue
DNA
Substrates

Keywords

  • Chemotherapy
  • DNA topoisomerase
  • Drug resistance
  • Human tumor
  • Topoisomerase inhibitor

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Structural Biology
  • Biophysics

Cite this

Clinical resistance to topoisomerase-targeted drugs. / Dingemans, Anne Marie C; Pinedo, Herbert M.; Giaccone, Giuseppe.

In: BBA - Gene Structure and Expression, Vol. 1400, No. 1-3, 01.10.1998, p. 275-288.

Research output: Contribution to journalArticle

Dingemans, Anne Marie C ; Pinedo, Herbert M. ; Giaccone, Giuseppe. / Clinical resistance to topoisomerase-targeted drugs. In: BBA - Gene Structure and Expression. 1998 ; Vol. 1400, No. 1-3. pp. 275-288.
@article{16d1e24f9f3247ee88bc9a9c92472d27,
title = "Clinical resistance to topoisomerase-targeted drugs",
abstract = "This review describes topoisomerase (topo)-mediated drug resistance and topo expression in human tissues and cancers. In some in vitro studies a relation has been observed between topo I, IIα or IIβ expression and sensitivity to topo inhibitors. Drug resistance to topo inhibitors may, however, be multifactorial. Several topo inhibitors are substrates for drug membrane transporters. As most topo inhibitors are cell cycle specific, disturbances in cell cycle regulation can also confer resistance, and downstream events following DNA damage induced by topo inhibitors may be involved in regulating cell death or survival. Several studies in patient specimens have shown a relation between topo IIα expression and the proliferative state of the tumor, higher topo IIα levels being seen in more highly proliferating tumor types. In contrast, topo IIβ appears to be expressed in both proliferating and quiescent cells. Furthermore, higher topo I levels were observed in some tumors when compared to their normal counterparts. In some studies a reduced topo IIα level was seen in samples taken after chemotherapy treatment, as compared with specimens prior to treatment. No unequivocal relation was observed, however, between expression or activity of the topo genes and response to chemotherapy; nonetheless only a few studies have properly addressed this question. This review summarizes the results of the clinical studies performed so far, and analyzes the critical issues in performing studies on patient material.",
keywords = "Chemotherapy, DNA topoisomerase, Drug resistance, Human tumor, Topoisomerase inhibitor",
author = "Dingemans, {Anne Marie C} and Pinedo, {Herbert M.} and Giuseppe Giaccone",
year = "1998",
month = "10",
day = "1",
doi = "10.1016/S0167-4781(98)00141-9",
language = "English (US)",
volume = "1400",
pages = "275--288",
journal = "Biochimica et Biophysica Acta - Gene Structure and Expression",
issn = "0167-4781",
publisher = "Elsevier BV",
number = "1-3",

}

TY - JOUR

T1 - Clinical resistance to topoisomerase-targeted drugs

AU - Dingemans, Anne Marie C

AU - Pinedo, Herbert M.

AU - Giaccone, Giuseppe

PY - 1998/10/1

Y1 - 1998/10/1

N2 - This review describes topoisomerase (topo)-mediated drug resistance and topo expression in human tissues and cancers. In some in vitro studies a relation has been observed between topo I, IIα or IIβ expression and sensitivity to topo inhibitors. Drug resistance to topo inhibitors may, however, be multifactorial. Several topo inhibitors are substrates for drug membrane transporters. As most topo inhibitors are cell cycle specific, disturbances in cell cycle regulation can also confer resistance, and downstream events following DNA damage induced by topo inhibitors may be involved in regulating cell death or survival. Several studies in patient specimens have shown a relation between topo IIα expression and the proliferative state of the tumor, higher topo IIα levels being seen in more highly proliferating tumor types. In contrast, topo IIβ appears to be expressed in both proliferating and quiescent cells. Furthermore, higher topo I levels were observed in some tumors when compared to their normal counterparts. In some studies a reduced topo IIα level was seen in samples taken after chemotherapy treatment, as compared with specimens prior to treatment. No unequivocal relation was observed, however, between expression or activity of the topo genes and response to chemotherapy; nonetheless only a few studies have properly addressed this question. This review summarizes the results of the clinical studies performed so far, and analyzes the critical issues in performing studies on patient material.

AB - This review describes topoisomerase (topo)-mediated drug resistance and topo expression in human tissues and cancers. In some in vitro studies a relation has been observed between topo I, IIα or IIβ expression and sensitivity to topo inhibitors. Drug resistance to topo inhibitors may, however, be multifactorial. Several topo inhibitors are substrates for drug membrane transporters. As most topo inhibitors are cell cycle specific, disturbances in cell cycle regulation can also confer resistance, and downstream events following DNA damage induced by topo inhibitors may be involved in regulating cell death or survival. Several studies in patient specimens have shown a relation between topo IIα expression and the proliferative state of the tumor, higher topo IIα levels being seen in more highly proliferating tumor types. In contrast, topo IIβ appears to be expressed in both proliferating and quiescent cells. Furthermore, higher topo I levels were observed in some tumors when compared to their normal counterparts. In some studies a reduced topo IIα level was seen in samples taken after chemotherapy treatment, as compared with specimens prior to treatment. No unequivocal relation was observed, however, between expression or activity of the topo genes and response to chemotherapy; nonetheless only a few studies have properly addressed this question. This review summarizes the results of the clinical studies performed so far, and analyzes the critical issues in performing studies on patient material.

KW - Chemotherapy

KW - DNA topoisomerase

KW - Drug resistance

KW - Human tumor

KW - Topoisomerase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0032190565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032190565&partnerID=8YFLogxK

U2 - 10.1016/S0167-4781(98)00141-9

DO - 10.1016/S0167-4781(98)00141-9

M3 - Article

VL - 1400

SP - 275

EP - 288

JO - Biochimica et Biophysica Acta - Gene Structure and Expression

JF - Biochimica et Biophysica Acta - Gene Structure and Expression

SN - 0167-4781

IS - 1-3

ER -